OakChart

Lucid Diagnostics Inc

LUCDHealthcare·Medical Devices·USA·Micro·NASD·Nov 11 • 8:26 AM ET

0.4211+0.0211 (5.27%)
2026-11-11 15:12 CET
Market cap
81.30 USD m
Revenue, TTM
5.45 USD m
Net income, TTM
-65.01 USD m
Free cash flow, TTM
-47.18 USD m
EPS diluted, TTM
-0.47
P/E
-
Compare

Price

LUCD against its 20, 50 and 200-day averages
2050200missearnings
0.250.500.751.001.2555.9M111.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LUCDclose 0.4220-day 0.4150-day 0.62200-day 0.990.42

74.2% under 1.63 on 21 Jan 2026. Last 15 sessions, 84.8% high to low

Profile

LUCD
52-week range, 9% of the way up
0.301.63

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.

IndexRUT
Employees82
IPOOct 14, 2021
Beta1.16
ATR, 14d0.06
Rel volume0.01
Short float9.36%
Insider own21.20%
Inst own27.78%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap85.59M
Enterprise Value77.10M
Income-65.01M
Sales5.45M
Book/sh0.06
Cash/sh0.16
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees82
IPOOct 14, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S15.70
P/B7.35
P/C2.56
P/FCF-
EV/EBITDA-
EV/Sales14.15
Quick Ratio1.30
Current Ratio1.33
Debt/Eq2.28
LT Debt/Eq0.05
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.47
EPS next Y-0.18
EPS next Q-0.06
EPS this Y37.21%
EPS next Y31.48%
EPS next 5Y28.07%
EPS past 3/5Y23.61% -25.34%
Sales past 3/5Y131.97% -
EPS Y/Y TTM55.16%
Sales Y/Y TTM24.89%
EPS Q/Q-0.88%
Sales Q/Q26.74%
EarningsNov 12 BMO
EPS/Sales Surpr.-5.82% 3.28%

Ownership

Insider Own21.20%
Insider Trans0.57%
Inst Own27.78%
Inst Trans16.43%
ROA-134.66%
ROE-556.27%
ROIC-457.21%
Gross Margin-37.78%
Oper. Margin-930.85%
Profit Margin-1193.87%
SMA201.79%
SMA50-32.43%
SMA200-57.58%
Trades-

Technical

Shs Outstand190.76M
Shs Float160.15M
Short Float9.36%
Short Ratio3.05
Short Interest14.99M
52W High1.63 -74.15%
52W Low0.30 38.98%
Volatility10.69% 15.52%
ATR (14)0.06
RSI (14)41.92
Beta1.16
Rel Volume0.01
Avg Volume4.92M
Volume2,045

Performance

Perf Week-5.39%
Perf Month-30.51%
Perf Quarter-56.36%
Perf Half Y-58.72%
Perf YTD-61.37%
Perf Year-59.51%
Perf 3Y-63.70%
Perf 5Y-95.64%
Perf 10Y-
Recom1.00
Target Price4.00
Prev Close0.40
Price0.42
Change %5.27%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Dec 27, 2021InitiatedAAscendiant Capital MarketsBuy$16+3,699.6%
Nov 08, 2021InitiatedNNeedhamBuy$17+3,937.0%
Nov 08, 2021InitiatedCCantor FitzgeraldOverweight$21+4,886.9%
Nov 08, 2021InitiatedBBTIG ResearchBuy$14+3,224.6%

Peers

Mkt cap
TickerCompanyMkt cap
CSTLCastle Biosciences Inc1.06B
SERASera Prognostics Inc79.14M
GHGuardant Health Inc21.17B
FRNMFreenome Inc1.18B
GRALGRAIL Inc5.78B
VCYTVeracyte Inc1.98B
BDSXBiodesix Inc105.90M
MDXHMDxHealth SA13.56M
NTRANatera Inc46.40B
PSNLPersonalis Inc1.72B

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Matheis DennisDirectorMay 20 '26Buy1.00245,000245,2701,033,443May 21 04:20 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
RSSLGlobal X Russell 2000 ETFAUM: 1.43B
VTHRVanguard Russell 3000 Index ETFAUM: 4.81B
ITWOProShares Russell 2000 High Income ETFAUM: 178.20M

News

latest 14 of 206
  • Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year (PR Newswire) -12.36%
  • Lucid Diagnostics Needs Proof Its Paid-Test Pivot Can Outrun A Shrinking Cash Pile (Earnings Whispers) +8.83%
  • Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (PR Newswire)
  • Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard Study (PR Newswire)
  • PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026 (PR Newswire) -6.36%
  • Loading…
  • Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026 (PR Newswire) +5.03%
  • Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard and Closes $15 Million Financing (PR Newswire) +25.42%
  • Lucid Diagnostics Advances Multiple EsoGuard and EsoCheck Payment, Billing and Coding Pathways (PR Newswire) +5.62%
  • PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results (PR Newswire)
  • Lucid Diagnostics Inc (LUCD) (Q2 2026) Earnings Call Highlights: Strategic Pivot to High-Value ... (GuruFocus.com)
  • Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results (PR Newswire)
  • Earnings To Watch: Lucid Diagnostics Inc (LUCD) Q2 2026 -- GF Value Sees 5% Upside (GuruFocus.com)
  • Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard Esophageal DNA Test (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.058--1.634
2026Q22026-08-13-0.060-0.057-0.0801.471.433
2026Q12026-05-14-0.070-0.063-0.1691.261.383
2025Q42026-03-26-0.100-0.093-0.1241.501.364
2025Q32025-11-12-0.100-0.095-0.0961.211.354
2025Q22025-08-13-0.100-0.114-0.0801.161.165
2025Q12025-05-14-0.160-0.148-0.5240.831.285
2024Q42025-03-24-0.190-0.178-0.1981.201.435
2024Q32024-11-13-0.200-0.206-0.2461.171.145
2024Q22024-08-12-0.200-0.200-0.2280.981.225
2024Q12024-05-13-0.990-0.240-0.4021.011.055
2023Q42024-03-26-1.330-0.230-0.2561.051.041
2023Q32023-11-13-0.220-0.238-0.3390.780.804
2023Q22023-08-14-0.230-0.283-0.2720.160.624
2023Q12023-05-15-0.240-0.325-0.3970.450.245
2022Q42023-03-13-0.330-0.330-0.4000.110.344

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-0.960-1.215-0.8040.500.50
2022FY-1.080-1.218-1.5530.380.58
2023FY-5.780-0.920-1.2612.452.43
2024FY-0.790-0.910-1.0504.354.57
2025FY-0.430-0.575-0.6904.714.56
2026FY--0.270--6.30
2027FY--0.185--16.71
2028FY--0.160--33.11
2029FY--0.090--36.80
2030FY--0.070--52.10

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-095011.631.481.80
2026Q3S2026-11-065021.631.481.80
2026Q3S2026-10-285021.631.481.82
2026Q3S2026-10-275031.631.481.82
2026Q3S2026-10-225131.631.481.82
2026Q3S2026-10-165221.641.481.82
2026Q3S2026-09-305131.631.481.82
2026Q3S2026-08-265131.631.481.80
2026Q3S2026-08-145121.711.482.00
2026Q3S2026-08-135201.951.482.75
2026Q3S2026-08-105011.921.422.75
2026Q3S2026-07-285001.941.422.75
2026Q3S2026-06-215041.941.422.75
2026Q3S2026-05-145051.941.422.75

Estimate history

EPS, annual-0.03-0.12-0.224-0.804-1.553-1.261-1.05-0.692-0.4692
Period20182019202020212022202320242025TTM
EPS, quarterly-0.228-0.246-0.198-0.524-0.08-0.096-0.124-0.169-0.08
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000.50.3772.4284.3464.7065.45
Period20182019202020212022202320242025TTM
Sales, quarterly0.9761.1721.1970.8281.1631.2111.5041.2561.474
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual36.99236.99236.99234.91840.51942.3363.072131.099190.757
Period20182019202020212022202320242025MRQ
Shares, quarterly49.34551.59863.07284.374101.827130.925131.099164.879190.757
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue5.454.714.352.430.380.500.000.000.00
Cost of Goods Sold Incl. D&A7.507.548.278.485.550.590.000.000.00
Gross Profit-2.06-2.84-3.92-6.05-5.17-0.090.000.000.00
Selling, General and Administrative Excl. Other48.6346.8042.1342.4351.0027.338.284.421.13
Research and Development5.395.685.997.2511.479.305.443.460.72
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-50.69-49.64-46.05-48.48-56.17-27.42-8.28-4.42-1.13
Interest Expense0.020.020.030.420.000.660.000.000.00
Unusual Expense1.918.73-0.234.190.000.000.000.000.00
Net Income Before Taxes-52.26-58.01-45.53-52.67-56.17-28.08-8.28-4.42-1.13
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-52.26-58.01-45.53-52.67-56.17-28.08-8.28-4.42-1.13
Net Income From Continuing Operations-52.26-58.01-45.53-52.67-56.17-28.08-8.28-4.42-1.13
Net Income-65.01-70.57-53.02-52.67-56.17-28.08-8.28-4.42-1.13
EPS (Recurring)-0.35-0.63-1.05-1.19-1.55-0.80-0.22-0.12-0.03
EPS (Basic, Before Extraordinaries)-0.47-0.69-1.05-1.26-1.55-0.80-0.22-0.12-0.03
EPS (Diluted)-0.47-0.69-1.05-1.26-1.55-0.80-0.22-0.12-0.03
EBITDA-49.81-48.77-44.88-45.98-54.23-27.41-8.28-4.42-1.13
Non-Operating Income (Expense)0.360.390.320.420.000.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.424.494.536.8214.999.600.070.170.04
Price To Sales Ratio35.9923.619.5224.25130.49375.02---
Gross Margin-37.78-60.26-90.20-249.18-1,372.15-17.80---
Operating Margin-930.85-1,054.82-1,059.64-1,996.79-14,899.47-5,483.80---
Net Margin-1,193.87-1,499.55-1,220.09-2,169.11-14,899.47-5,615.60---
Shares Outstanding190.76131.1063.0742.3340.5234.9236.9936.9936.99
Market Capitalization81.3081.3048.5859.6950.34198.65191.62--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue1.471.261.501.211.160.831.201.17
Cost of Goods Sold Incl. D&A1.671.852.071.921.781.772.371.90
Gross Profit-0.20-0.59-0.56-0.71-0.62-0.94-1.17-0.73
Selling, General and Administrative Excl. Other12.6111.5213.4511.0510.7611.5411.2110.97
Research and Development1.191.211.721.271.251.431.451.67
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-12.80-12.11-14.01-11.76-11.38-12.49-12.38-11.69
Interest Expense0.000.010.010.000.010.010.010.00
Unusual Expense-1.041.862.36-1.26-6.8414.48-0.780.76
Net Income Before Taxes-11.69-13.91-16.27-10.40-4.44-26.91-11.54-12.37
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-11.69-13.91-16.27-10.40-4.44-26.91-11.54-12.37
Net Income From Continuing Operations-11.69-13.91-16.27-10.40-4.44-26.91-11.54-12.37
Net Income-14.71-23.63-16.27-10.40-7.89-36.02-11.54-12.37
EPS (Recurring)-0.08-0.16-0.11-0.10-0.13-0.38-0.21-0.24
EPS (Basic, Before Extraordinaries)-0.08-0.17-0.12-0.10-0.08-0.52-0.20-0.25
EPS (Diluted)-0.08-0.17-0.12-0.10-0.08-0.52-0.20-0.25
EBITDA-12.58-11.89-13.80-11.54-11.16-12.27-12.15-11.48
Non-Operating Income (Expense)0.080.070.110.100.110.070.070.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.691.411.171.151.141.031.171.23
Price To Sales Ratio35.9931.3830.3624.8426.1124.5611.009.80
Gross Margin-13.23-47.05-37.57-58.30-53.48-114.01-97.74-62.03
Operating Margin-868.45-964.49-931.58-971.02-978.85-1,508.09-1,033.83-997.78
Net Margin-998.30-1,881.21-1,081.52-858.55-678.25-4,350.00-964.16-1,055.55
Shares Outstanding190.76164.88131.10130.92101.8384.3763.0751.60
Market Capitalization81.30203.49142.90138.60124.42129.4248.5844.00

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments34.7022.3618.9022.4753.660.110.160.02
Short Term Receivables0.640.410.040.020.200.000.000.00
Inventories0.710.920.000.000.000.000.000.00
Other Current Assets1.411.463.131.863.451.330.230.00
Total Current Assets37.4725.1522.0724.3657.301.440.390.02
Net Property, Plant & Equipment2.623.702.643.600.970.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.00
Intangible Assets0.320.741.423.44---0.00
Other Assets0.051.131.131.110.720.760.640.00
Total Assets40.4530.7127.2732.5159.002.191.030.02
Short Term Debt Incl. Current Port. of LT Debt24.8919.4515.060.960.000.000.000.00
Accounts Payable0.971.241.151.061.492.060.800.50
Other Current Liabilities2.722.8313.186.412.7713.665.540.58
Total Current Liabilities28.5823.5229.388.434.2615.716.341.08
Long Term Debt0.931.800.201.040.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.00
Total Liabilities29.5125.3229.589.464.2615.716.341.08
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value54.2754.4218.620.000.000.000.000.00
Common Equity-43.34-49.03-20.9423.0554.74-13.52-5.31-1.06
Total Shareholders Equity10.945.39-2.3123.0554.74-13.52-5.31-1.06
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity10.945.39-2.3123.0554.74-13.52-5.31-1.06
Total Liabilities & Stockholders Equity40.4530.7127.2732.5159.002.191.030.02
Book Value Per Share-0.33-0.78-0.490.571.57-0.37-0.14-0.03
Tangible Book Value Per Share-0.33-0.79-0.530.481.57-0.37-0.14-0.03
Full-Time Employees82727074----
Price to Book Ratio6.98-0.85-5.391.833.43-7.90--
Return on Assets-163.04-157.04-176.20-122.77-91.77-512.86-840.65-
Return on Equity-710.60-2,956.43-507.97-144.42-136.23---
Return on Invested Capital-489.00-633.14--233.23-51.29---
Quick Ratio1.291.030.752.8913.450.090.060.02
Current Ratio1.311.070.752.8913.450.090.060.02

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-52.26-58.01-45.53-52.67-56.17-28.08-8.28-4.42-1.13
Depreciation0.880.871.172.501.940.00---
Other Funds (Non Cash)7.4813.464.6511.6815.649.600.070.170.29
Funds from Operations-43.90-43.68-39.71-38.49-38.59-18.48-8.21-4.25-0.83
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.96-2.81-4.435.678.910.812.591.890.72
Cash from Operating Activities-46.87-46.48-44.14-32.82-29.68-17.67-5.63-2.36-0.11
Capital Expenditures-0.32-0.20-0.65-0.22-0.91-0.860.000.000.00
Net Assets From Acquisitions0.000.000.000.00-3.200.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.32-0.20-0.65-0.22-4.11-0.860.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock49.4858.6730.2529.462.6177.745.582.500.13
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock49.4858.6730.2529.462.6177.745.582.500.13
Proceedsfrom Stock Options49.1258.3830.2529.461.9277.745.582.500.13
Issuance or Reduction of Debt, Net0.000.3618.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.020.000.000.000.00-5.660.000.000.00
Other Financing Activities Uses-0.020.000.000.000.00-5.660.000.000.00
Cash from Financing Activities49.4759.0348.2529.462.6172.085.582.500.13
Net Change in Cash2.2812.353.46-3.58-31.1853.55-0.050.140.02
Free Cash Flow-47.18-46.68-44.44-33.04-30.59-18.53-5.63-2.36-0.11
Preferred Dividends (Cash Flow)----0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments33.4027.8834.7047.3331.1225.24
Short Term Receivables1.090.690.640.550.370.06
Inventories0.871.000.710.860.981.08
Other Current Assets1.261.801.411.101.361.16
Total Current Assets36.6231.3637.4749.8433.8327.54
Net Property, Plant & Equipment2.212.502.622.883.193.49
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.100.210.320.420.530.63
Other Assets0.010.010.050.051.121.13
Total Assets38.9534.0840.4553.2038.6732.80
Short Term Debt Incl. Current Port. of LT Debt24.4126.1124.8923.1826.1733.67
Accounts Payable0.671.080.970.750.830.83
Other Current Liabilities2.442.202.722.282.422.07
Total Current Liabilities27.5229.3928.5826.2129.4336.57
Long Term Debt0.500.690.931.161.381.60
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities28.0230.0829.5127.3630.8138.17
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.0010.1354.2754.2754.4254.42
Common Equity10.93-6.13-43.34-28.44-46.56-59.80
Total Shareholders Equity10.934.0010.9425.847.86-5.38
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity10.934.0010.9425.847.86-5.38
Total Liabilities & Stockholders Equity38.9534.0840.4553.2038.6732.80
Book Value Per Share0.06-0.04-0.33-0.22-0.46-0.71
Tangible Book Value Per Share0.06-0.04-0.33-0.22-0.46-0.72
Full-Time Employees--82---
Price to Book Ratio6.98-3.48-5.02-2.21-1.62-1.92
Return on Assets-134.66-134.61-163.04-140.60-151.85-190.69
Return on Equity-556.27--710.60-331.24-463.56-1,897.35
Return on Invested Capital-102.25-296.25-137.12-38.52-48.02-
Quick Ratio1.301.031.291.871.120.72
Current Ratio1.331.071.311.901.150.75

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-11.69-13.91-16.27-10.40-4.44-26.91
Depreciation0.220.220.210.220.220.22
Other Funds (Non Cash)0.683.303.52-0.02-5.6215.58
Funds from Operations-10.78-10.39-12.53-10.20-9.84-11.11
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.52-1.71-0.04-0.69-0.71-1.36
Cash from Operating Activities-11.30-12.10-12.58-10.89-10.55-12.46
Capital Expenditures-0.02-0.21-0.05-0.03-0.03-0.09
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.02-0.21-0.05-0.03-0.03-0.09
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock16.855.500.0027.1316.4615.08
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock16.855.500.0027.1316.4615.08
Proceedsfrom Stock Options16.845.270.0027.0016.4514.93
Issuance or Reduction of Debt, Net0.000.000.000.000.000.36
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.020.000.000.000.00
Other Financing Activities Uses0.00-0.020.000.000.000.00
Cash from Financing Activities16.855.490.0027.1316.4615.44
Net Change in Cash5.53-6.83-12.6316.215.882.88
Free Cash Flow-11.32-12.32-12.63-10.92-10.57-12.56

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 4.35M 2025: 4.71M
United States2024: 4.35M 2025: 4.71M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.36%15.0M160.2M4.85M
2026-10-158.51%13.6M160.2M1.36M
2026-09-308.40%13.5M160.2M1.22M
2026-09-158.01%12.8M160.2M1.42M
2026-08-317.43%11.9M160.1M1.38M
2026-08-148.01%12.8M160.1M1.43M
2026-07-317.58%12.1M160.0M1.40M
2026-07-156.81%10.9M160.0M1.30M
2026-06-305.89%9.4M160.0M1.16M
2026-06-154.64%7.4M160.0M835.12K
2026-05-293.98%6.1M153.7M811.04K
2026-05-154.31%6.6M153.7M782.38K
2026-04-304.44%5.9M133.8M771.55K
2026-04-154.66%6.2M133.6M1.34M
2026-03-314.77%5.9M124.5M1.31M
2026-03-136.29%5.8M92.2M1.32M
2026-02-277.29%6.7M92.2M1.31M
2026-02-137.88%7.3M92.2M1.30M
2026-01-307.60%7.0M92.3M1.26M
2026-01-154.11%3.8M92.3M654.06K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-228-KCurrent report2026-10-21SEC
2026-10-168-KCurrent report2026-10-12SEC
2026-09-228-KCurrent report2026-09-22SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-06-248-KCurrent report2026-06-24SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-30ARSAnnual report to security holders. 2025-12-31SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-30SEC
2026-04-248-KCurrent report2026-04-24SEC
2026-04-243/A2026-03-23SEC
2026-04-23424B5SEC
2026-04-238-KCurrent report2026-04-23SEC
2026-04-20PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-20SEC
2026-04-133Initial statement of beneficial ownership of securities2026-03-23SEC
2026-04-03S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-04-03S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-26EFFECTEffectiveness filing by commission orderSEC
2026-03-26424B5SEC
2026-03-268-KCurrent report2026-03-26SEC
2026-03-26S-3/ASEC
2026-03-25CORRESPSEC
2026-03-2510-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-244Statement of changes in beneficial ownership of securities2026-02-20SEC
2026-02-244Statement of changes in beneficial ownership of securities2026-02-20SEC
2026-02-244Statement of changes in beneficial ownership of securities2026-02-20SEC
2026-02-244Statement of changes in beneficial ownership of securities2026-02-20SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-05245.27K100
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Alyeska Investment Group, L.P.4.36%
BlackRock, Inc.4.12%
VANGUARD CAPITAL MANAGEMENT LLC3.23%
Two Seas Capital LP2.95%
Aberdeen Group plc2.17%
MASTERS CAPITAL MANAGEMENT LLC1.97%
GEODE CAPITAL MANAGEMENT, LLC1.75%
STATE STREET CORP1.20%
FIRST MANHATTAN CO. LLC.1.08%
WELLS FARGO & COMPANY/MN1.02%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.24%
abrdn Healthcare Opportunities Fund1.88%
iShares Russell 2000 ETF1.76%
VANGUARD EXTENDED MARKET INDEX FUND0.92%
Fidelity Small Cap Index Fund0.78%
iShares Russell 2000 Growth ETF0.69%
VANGUARD RUSSELL 2000 INDEX FUND0.42%
Fidelity Extended Market Index Fund0.39%
iShares Micro-Cap ETF0.25%
Schwab Small-Cap Index Fund0.18%

OakChart. LUCD. Cached 15 minutes.